Selank dosage is one of the most frequently searched topics related to this peptide. Unlike conventional medications, Selank does not currently have universally accepted dosage guidelines developed from large international clinical trials. Most of the available information comes from Russian clinical studies, experimental research, animal models, and observational protocols used in research settings.
Because the dosage can vary depending on the study's purpose, route of administration, and individual physiological response, it is worth understanding the dose ranges that have been used in the available scientific literature. For more information on the properties and mechanisms of action of this peptide, please refer to our main guide regarding Selank.
What doses of Selank were used in studies?
Selank has primarily been studied as a peptide administered intranasally, and this is the most commonly described route of administration in both scientific research and clinical practice.
Human studies investigating anxiety, stress adaptation, cognitive function, and neuropsychiatric effects have predominantly used nasal administration, rather than injectable forms [1–4].
In animal studies, a wide range of doses was used depending on the experimental model. For example, long-term studies using the Selank analogue TP-7 applied a dose of 0.3 mg/kg daily and showed a significant reduction in anxiety-related behaviours after four weeks of administration [5].
Laboratory studies analysing the modulation of GABA receptors, regulation of BDNF, antiviral activity, immune response, and gene expression also used various dosing regimens that cannot be directly translated to humans [6–9].
Typical Selank Dosage Ranges Discussed in Clinical Practice
Based on published literature and commonly discussed peptide protocols, Selank is typically administered in amounts expressed in micrograms.
The most common daily ranges include:
| Level of experience | Typical daily range |
|---|---|
| Low dose | 250–500 mcg per day |
| Moderate dose | 500–1000 mcg per day |
| Higher dose | 1000–2000 mcg daily |
When administered nasally, doses are often divided into several applications throughout the day.
It should be stressed that the given ranges reflect clinical practice and observational peptide protocols, rather than internationally approved therapeutic guidelines.
Selank dosage for anxiety
Many people seeking information on Selank dosage are interested in its potential effects on anxiety and stress management. Research suggests that Selank may support emotional balance through several biological mechanisms.
Laboratory studies indicate that Selank acts as a positive allosteric modulator of GABA receptors, supporting proper inhibitory neurotransmission in the brain [1]. Additionally, it has been shown to inhibit enzymes responsible for the breakdown of enkephalins – natural neuropeptides involved in mood regulation and stress adaptation [10].
Research has also shown an impact on neurotransmitter systems involved in emotional regulation and on neurotrophic factors, such as BDNF (brain-derived neurotrophic factor), which plays an important role in neuroplasticity and neuronal resilience [1,3,7].
In contrast to benzodiazepines, Selank does not appear to exert its effects through direct receptor activation and may not produce an immediate calming effect. Its action may develop gradually by modulating multiple regulatory systems.
Dosage of Selank for Cognitive Function Support
Research into the effects of Selank on cognitive functions suggests that the peptide may interact with processes related to memory, learning, concentration, neuroplasticity, and cognitive functioning under stress [3,7].
For this reason, Selank is often compared with Semax. Although both peptides originate from the Russian peptide research programme, their main scientific focuses differ. Semax is more often studied for the improvement of cognitive functions and neuroprotection, whereas Selank is primarily associated with anxiety regulation, emotional balance, and stress resistance [3].
Selank 10 mg – How Long Does a Vial Last?
One of the common questions is how long a vial containing 10 mg of Selank may last. The answer depends entirely on the amount used each day.
For example:
| Daily allowance | Approximate usage time for a 10 mg vial |
|---|---|
| 250 mcg per day | Around 40 days |
| 500 mcg/day | Around 20 days |
| 1000 mcg/dzień | Around 10 days |
| 2000 mcg/day | Around 5 days |
Actual protocols can vary significantly and should be established by qualified professionals, where applicable.
Selank intranasally or subcutaneously?
Nasal spray
Most published research on Selank involves intranasal administration, as this was the original route of administration used in clinical and experimental studies [2,7].
Scientists point to several potential advantages of this method, including non-invasiveness, rapid absorption by the nasal mucosa, and widespread use in historical research programmes concerning Selank.
Subcutaneous Injection
Protocols utilising subcutaneous administration of Selank are frequently discussed in peptide enthusiast communities, however, there are significantly fewer scientific publications available compared to nasal administration.
Due to the limited number of human clinical trials, evidence-based recommendations for Selank dosing via injection have not currently been established.
How often is Selank used?
Research protocols varied significantly depending on the study design and the objective analysed.
Some mechanistic studies have analysed single administration [1]. Studies related to anxiety have often used daily administration [5], whereas other behavioural experiments have involved multi-week treatment regimens [5]. Additional neurobiological studies concerning BDNF regulation and neurotransmitter activity have also used different intranasal administration schedules [7].
As large, long-term clinical trials are still lacking, the optimal frequency of use remains undetermined.
Does a higher dose of Selank mean better effects?
The currently available data do not indicate that higher doses automatically lead to better results.
Research suggests that Selank affects multiple regulatory systems, including GABA signalling, endogenous opioid pathways, neurotrophic factors, neurotransmitter regulation, and immune responses [1,7,10]. These systems often exhibit non-linear biological responses, meaning that increasing the dose beyond a certain level may not proportionally increase the observed effects.
For this reason, researchers emphasise the importance of an individualised approach rather than assuming that more automatically means more benefits.
Key Information
Selank is most commonly studied as a nasal peptide and is primarily analysed for its potential effects on anxiety reduction, stress resilience, cognitive function support, emotional regulation, and nervous system functioning.
Currently, there are no widely accepted dosing guidelines. The most commonly discussed daily ranges are between 250 and 2000 mcg, however, these values are based mainly on clinical practice and observational research protocols, rather than on internationally approved recommendations.
Most mechanistic and clinical data originate from Russian research programmes and smaller studies. Large-scale clinical trials are needed to determine optimal dosing strategies, long-term safety, and efficacy.
Disclaimer
The content presented in this article is for educational and informational purposes only. It does not constitute medical advice, diagnosis, treatment or recommendations regarding dosage. Selank is not approved for all uses in many countries and standardised dosing guidelines have not been established based on large international clinical trials. Any decisions regarding therapy with peptides should be consulted with a qualified healthcare professional.
For research purposes only: The Selank products offered by Semax Polska are intended solely for laboratory and scientific research. They are not intended for human consumption or for use in the diagnosis, treatment, prevention or alleviation of any diseases. Researchers should use these materials in accordance with applicable laws, regulations and standards governing scientific research.
References
[1] Vyunova, T. V., Andreeva, L. A., Shevchenko, K. V., & Myasoedov, N. F. (2018). Peptide-based anxiolytics: The molecular aspects of the heptapeptide Selank's biological activity. Protein and Peptide Letters, 25(10), 914–923. https://doi.org/10.2174/0929866525666180925144642
[2] Prakhye, I. et al. (2017). Behavioural Neurology review discussing the neurobiological and clinical effects of Selank. Behavioral Neurology. https://onlinelibrary.wiley.com/doi/full/10.1155/2017/5091027
[3] PubChem. (2026). Selank Compound Summary. National Centre for Biotechnology Information. https://pubchem.ncbi.nlm.nih.gov/compound/Selank
[4] Letters to the Journal of Experimental and Clinical Pharmacology. Clinical and pharmacological investigations involving Selank. https://www.pismin.com/10.1134/S1062359019040071
[5] Czabak-Garbacz, R., Cygan, B., Wolański, Ł., & Kozlovsky, I. (2006). Influence of long-term treatment with tuftsin analogue TP-7 on anxiety-phobic states and body weight. Pharmacological Reports, 58(4), 562–567. PMID: 16963804
[6] Kost, N. V., Sokolov, O. Y., Zozulya, S. A., & Myasoedov, N. F. (2025). Combined action of benzodiazepine tranquilizers and peptide anxiolytic Selank in BALB/c mice. Neurochemical Journal, 19, 743–748. https://doi.org/10.1134/S1819712425700783
[7] Levitskaya, N. G., Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Doklady Biological Sciences, 431, 79–82. Available from: https://www.researchgate.net/profile/Natalia-Levitskaya/publication/23306196
[8] Andreeva, L. A., Nagaev, I. Y., Mezentseva, M. V., Shapoval, I. M., Podchernyaeva, R. Y., Shcherbenko, V. E., Potapova, L. A., Russu, L. I., Ershov, F. I., & Myasoedov, N. F. (2010). Antiviral properties of structural fragments of the peptide Selank. Doklady Biological Sciences, 431(1), 79–82. https://doi.org/10.1134/S0012496610020031
[9] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborskaya, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2014). Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischaemia. Molecular Biology, 48(2), 277–287. PMID: 25850296
[10] Zozulya, A. A., Kost, N. V., Sokolov, O. Y., Gabaeva, M. V., Grivennikov, I. A., Andreeva, L. N., Zolotarev, Y. A., Ivanov, S. V., Andryushchenko, A. V., Myasoedov, N. F., & Smulevich, A. B. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine, 131(4), 315–317. https://doi.org/10.1023/A:1017979514274